ARPA-H Pours $144 Million Into Aging Research Through PROSPR Program
March 28, 2026 · 2 min read
Jared Klein
The Advanced Research Projects Agency for Health is backing a radical bet: that aging itself can be treated as a biological problem with measurable interventions. The agency's PROSPR program — Proactive Solutions for Prolonging Resilience — is allocating up to $144 million across seven research teams working to extend human healthspan through therapies that would have been considered science fiction a decade ago.
The program's core innovation is methodological. Rather than waiting decades to observe age-related outcomes, PROSPR teams must identify early biomarkers that respond within one to three years, demonstrating whether interventions can shift individuals toward better physical and metabolic function.
Who Is Getting Funded
Two of the largest awards illustrate PROSPR's ambition. Cambrian Biotech received up to $30.8 million to conduct human trials of a next-generation rapamycin analog targeting the mTORC1 signaling pathway, measuring success through "intrinsic capacity" — a composite metric of physical and metabolic resilience. Linnaeus was awarded up to $22 million to advance a drug targeting the G protein-coupled estrogen receptor (GPER) into human trials, building on oncology research involving over 100 cancer patients.
These are not basic research grants. ARPA-H is funding clinical trials designed to produce regulatory-grade evidence within compressed timelines — the agency's signature approach borrowed from DARPA's playbook of high-risk, high-reward investment.
What This Means for Biotech Grant Seekers
PROSPR signals that longevity and healthspan research has moved from the fringes of philanthropy into the center of federal health innovation funding. Companies and research teams working on senolytics, mTOR pathway modulators, epigenetic reprogramming, or biomarker development should monitor ARPA-H for follow-on solicitations.
ARPA-H continues to post open funding opportunities across its three offices, with new programs announced regularly. Grant seekers can track ARPA-H and other federal health funding opportunities on grantedai.com.
For analysis of ARPA-H's expanding portfolio, visit the Granted blog.